Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Receivables (2016 - 2023)

Historic Receivables for Avalo Therapeutics (AVTX) over the last 8 years, with Q2 2023 value amounting to $44000.0.

  • Avalo Therapeutics' Receivables fell 9762.16% to $44000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $44000.0, marking a year-over-year decrease of 9762.16%. This contributed to the annual value of $1.9 million for FY2022, which is 6001.25% down from last year.
  • According to the latest figures from Q2 2023, Avalo Therapeutics' Receivables is $44000.0, which was down 9762.16% from $1.9 million recorded in Q4 2022.
  • In the past 5 years, Avalo Therapeutics' Receivables ranged from a high of $8.2 million in Q1 2019 and a low of $44000.0 during Q2 2023
  • For the 5-year period, Avalo Therapeutics' Receivables averaged around $3.9 million, with its median value being $4.3 million (2020).
  • In the last 5 years, Avalo Therapeutics' Receivables soared by 7164.4% in 2019 and then plummeted by 9762.16% in 2023.
  • Avalo Therapeutics' Receivables (Quarter) stood at $5.2 million in 2019, then decreased by 16.35% to $4.4 million in 2020, then rose by 9.44% to $4.8 million in 2021, then tumbled by 60.01% to $1.9 million in 2022, then tumbled by 97.71% to $44000.0 in 2023.
  • Its last three reported values are $44000.0 in Q2 2023, $1.9 million for Q4 2022, and $1.3 million during Q3 2022.